General Drug House Ltd., Bangkok   Report issue

For profit Phase 3
Founded: Bangkok Thailand (1959)
Status: No NME R&D (1959)

Organization Overview

First Clinical Trial
2007
NCT01706627
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Alternative names

General Drugs House Ltd., Bangkok

Active Ingredients

Drugs in Phase 3 Trials (1)

melatonin (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Head and Neck Neoplasms (Phase 2)

Mucositis (Phase 2)

Stomatitis (Phase 2)

Xerostomia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 1